Treatment-Induced Ovarian Insufficiency and Early Menopause in Breast Cancer Survivors

Young women receiving systemic treatments for breast cancer are at risk for developing primary ovarian insuffciency and early menopause. Abrupt drops in estrogen levels often induce distressing vasomotor and vulvovaginal symptoms. Sustained estrogen deficiency related to treatment-induced early menopause can negatively affect long-term health outcomes. This article reviews the etiology of treatment-induced ovarian insuffciency and early menopause, discusses the effects of hypoestrogenism, and explores supportive care strategies to improve quality of life and long-term health for young breast cancer survivors. AT A GLANCE ɔ In premenopausal women, gonadotoxic chemotherapy agents and endocrine therapies can inhibit ovarian function and disrupt the physiologic effects of estrogen. ɔ Pharmacologic and nonpharmacologic management options are available for the sequelae of hypoestrogenism in this population. ɔ Nurses can support young breast cancer survivors by regularly assessing for menopausal symptoms, providing education and anticipa-tory guidance, and using an interprofessional approach to patient needs. © 2023, Oncology Nursing Society. All rights reserved.